Forty years ago, with a small group of people armed with few resources but with many hopes and dreams, ELPEN began creating what would soon become a life time goal, a powerful and dynamic Greek pharmaceutical company.
Based on strategic planning, which includes international collaborations on several projects including proprietary Dry Powder Inhaler technology, the Elpenhaler®, and increasing resource allocation in the sector of research, ELPEN plans to expand into even more challenging goals.
The Elpenhaler® is Elpen's proprietary, Patent Protected, Breath-Activated, Multi Single-Dose Dry Powder Inhaler, initially developed for the administration of anti-asthma and COPD medications, which are packed in a specially designed single dose alu-alu blister strips.
ELPEN is seeking to license-out the Elpenhaler® line of anti-asthma and COPD products, which currently include products with active ingredients formoterol, fluticasone and selected combinations.
- Core Sales Territory:
Global Regulated Markets